GRAND PLAN Study | In order to achieve the WHO objective to eliminate HCV infection as a public health concern by 2030, short course of all oral, highly effective and well tolerated treatment regimens will be important in engaging infected active drug users.
Glecaprevir/pibrentasvir for the treatment of hepatitis C virus infection among active drug users: the GRAND PLAN study Presented at the Canadian Liver Meeting, February 28- March 1, Montreal, Canada, 2020.